NCT00000891View on ClinicalTrials.gov

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

Not specified

Study Completion Date

May 31, 2004

Conditions

HIV Infections

Interventions

DRUG

Ritonavir

DRUG

Saquinavir

DRUG

Delavirdine mesylate

DRUG

Lamivudine

DRUG

Stavudine

DRUG

Zidovudine

DRUG

Didanosine

Trial Locations (3)

44106

Case Western Reserve Univ, Cleveland

60612

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

80262

Univ of Colorado Health Sciences Ctr, Denver

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000891 - Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 | Biotech Hunter | Biotech Hunter